Analysis of IL-13 receptor structure identifies three different types of receptors which utilize two different types of cloned IL-13R alpha chains (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Analysis of IL-13 receptor structure identifies three different types of receptors which utilize two different types of cloned IL-13R alpha chains (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 38:A440 1997. Unique Identifier : AIDSLINE MED/97619122
Murata T; Obiri N; Puri R; Division of Cellular and Gene Therapy, CBER, FDA, Bethesda, MD 20892

Abstract: We recently reported that IL-13 receptor (R) can be classified into at least three major types based on the patterns of IL-13 binding and interaction with IL-4. Recently, two different human IL-13R chains have been cloned from Caki-1 renal cell carcinoma RCC) and MT-2 HTLV-1 infected T cell lines (termed here alpha and alpha'), respectively. To investigate which IL-13R chain is utilized in each type of IL-13R, we examined various cell lines for the expression of mRNA for both IL-13R chains, IL-4R p140 and gammac chain by RT-PCR. In type I IL-13R (RCC, U251 glioblastoma and IGROV-1 ovarian carcinoma), both IL-13Ralpha and alpha' chains were expressed. In type II IL-13R users (HT-29 human colon carcinoma, A431 epidermoid carcinoma and PA-1 ovarian carcinoma), IL-13R alpha' but not alpha was expressed. In hematopoietic cells, (EBV-B cells and TF-1 myeloid cell line) IL-13R alpha' but not IL-13R alpha chain was expressed along with IL-4R p140 and gammac (type III IL-13R). However, neither IL-13R chains were detected in human T cell line, H9 and the gibbon T cell line MLA-144. These data suggest that type I IL-13R consist of a dimmer of alpha and alpha'. On the other hand, type II IL-13R consist of IL-13R alpha' and IL-4R p140 and type III IL-13R may consist of IL-13R alpha', IL-4R p140, and gammac.

Keywords: *Adenocarcinoma/METABOLISM *Carcinogens/METABOLISM *Lung Neoplasms/METABOLISM *Nitrosamines/METABOLISM *Receptors, Cholinergic/METABOLISM
971030
M97A1341

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .